BMRN Biomarin Pharmaceutical
- 77.050
- -0.510-0.66%
- 77.050
- 0.0000.00%
Biomarin Pharmaceutical News
Li Auto Was One Of The Worst-Performing Stocks Last Week: Are These 10 Large-Cap Stocks Losers In Your Portfolio? (May 12-May 18, 2024)
These 10 large-cap stocks were the worst performers last week. Are they in your portfolio?
Walmart To Rally Over 17%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Piper Sandl
BioMarin Pharmaceutical Cut to Neutral From Outperform by Baird
BioMarin Pharmaceutical Cut to Neutral From Outperform by Baird
Analysts Are Bullish on These Healthcare Stocks: BioMarin Pharmaceutical (BMRN), Ionis Pharmaceuticals (IONS)
Baird: Biomarin Pharmaceutical (BMRN.US) rating was downgraded from superior to market neutral, and the target price was adjusted from $104.00 to $72.00.
Baird: Biomarin Pharmaceutical (BMRN.US) rating was downgraded from superior to market neutral, and the target price was adjusted from $104.00 to $72.00.
Baird Downgrades Biomarin Pharmaceutical to Neutral, Lowers Price Target to $72
Baird analyst Joel Beatty downgrades Biomarin Pharmaceutical (NASDAQ:BMRN) from Outperform to Neutral and lowers the price target from $104 to $72.
Third Point Top Buy and Sells in Q1
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities.
BioMarin Pharmaceutical To Cut About 170 Employees
BioMarin Pharmaceutical To Cut About 170 Employees
Is There An Opportunity With BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) 47% Undervaluation?
Key Insights The projected fair value for BioMarin Pharmaceutical is US$152 based on 2 Stage Free Cash Flow to Equity BioMarin Pharmaceutical's US$80.50 share price signals that it might be 47% unde
BioMarin Pharmaceutical Initiated at Outperform by Evercore ISI Group
BioMarin Pharmaceutical Initiated at Outperform by Evercore ISI Group
Evercore ISI Group Initiates Coverage On Biomarin Pharmaceutical With Outperform Rating, Announces Price Target of $113
Evercore ISI Group analyst Cory Kasimov initiates coverage on Biomarin Pharmaceutical (NASDAQ:BMRN) with a Outperform rating and announces Price Target of $113.
Biomarin Pharmaceutical Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/14/2024 41.25% Evercore ISI Group → $113 Initiates Coverage On → Outperform 04/26/2024 40% Morgan Stanl
Biomarin Pharmaceutical(BMRN.US) Director Sells US$3.26 Million in Common Stock
$Biomarin Pharmaceutical(BMRN.US)$ Director BIENAIME JEAN JACQUES sold 40,000 shares of common stock on May 9, 10, 2024 at an average price of $81.38 for a total value of $3.26 million.Source: Announc
Biomarin Pharmaceutical Insider Sold Shares Worth $3,255,200, According to a Recent SEC Filing
Jean Jacques Bienaime, Director, on May 09, 2024, sold 40,000 shares in Biomarin Pharmaceutical (BMRN) for $3,255,200. Following the Form 4 filing with the SEC, Bienaime has control over a total of 72
Form 144 | Biomarin Pharmaceutical(BMRN.US) Director Proposes to Sell 1.62 Million in Common Stocks
SEC FILLINGS DISCLOSED/ May 10, $Biomarin Pharmaceutical(BMRN.US)$ Director BIENAIME JEAN JACQUES intends to sell 20,000 shares of its common stock on May 10, with a total market value of approximatel
(BMRN) - Analyzing Biomarin Pharmaceutical's Short Interest
Biomarin Pharmaceutical's (NYSE:BMRN) short percent of float has risen 20.25% since its last report. The company recently reported that it has 3.69 million shares sold short, which is 1.96% of all reg
Form 144 | Biomarin Pharmaceutical(BMRN.US) Director Proposes to Sell 1.63 Million in Common Stocks
SEC FILLINGS DISCLOSED/ May 9, $Biomarin Pharmaceutical(BMRN.US)$ Director BIENAIME JEAN JACQUES intends to sell 20,000 shares of its common stock on May 9, with a total market value of approximately
BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NV
SAN RAFAEL, Calif., May 8, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President, and Chief Executive Officer of BioMarin will present at th
Biomarin Pharmaceutical(BMRN.US) Officer Sells US$157.27K in Common Stock
$Biomarin Pharmaceutical(BMRN.US)$ Officer Davis George Eric sold 1,850 shares of common stock on May 2, 2024 at an average price of $85.01 for a total value of $157.27K.Source: Announcement What is s
Analysis
Price Target
No Data
